Laboratory and clinical studies on cefprozil granules in pediatrics

H. Akita, Y. Sato, S. Iwata, K. Sunakawa

Research output: Contribution to journalArticle

Abstract

Fundamental and clinical effects of cefprozil (CFPZ, BMY-28 100) granules, a new oral cephalosporin antibiotic, in pediatric field were investigated. The result obtained were summarized as follows. CFPZ (10% granules) was given to 1 child in a single dose of 7.5 mg/kg. The peak serum concentration of CFPZ was 4.51 μg/ml at 2 hours after administration. Half-life and AUC values were 0.98 hour and 20.7 μg · hr/ml. The mean peak urinary concentrations of CFPZ and 6 hours recovery rates were over 200 μg/ml at 2~6 hours and 27.6%, respectively. Clinical efficacy of CFPZ was investigated in a total of 41 children, including 14 with upper respiratory tract infections, 6 with acute bronchitis and pneumonia, 2 with acute otitis media, 3 with skin and soft tissue infections and 16 with urinary tract infections. The clinical efficacy rate was 95.1%. The bacteriological eradication rate was 84.6%. Two patients showed abnormal laboratory test results. One had elevations of both GOT and GPT, and another had eosinophilia which were attributed to this antibiotic as side effects.

Original languageEnglish
Pages (from-to)1526-1536
Number of pages11
JournalJapanese Journal of Antibiotics
Volume45
Issue number11
Publication statusPublished - 1992
Externally publishedYes

Fingerprint

Pediatrics
Soft Tissue Infections
Bronchitis
Otitis Media
Eosinophilia
Cephalosporins
Urinary Tract Infections
Respiratory Tract Infections
Area Under Curve
Half-Life
Pneumonia
Anti-Bacterial Agents
Skin
Serum
cefprozil
Clinical Studies

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Akita, H., Sato, Y., Iwata, S., & Sunakawa, K. (1992). Laboratory and clinical studies on cefprozil granules in pediatrics. Japanese Journal of Antibiotics, 45(11), 1526-1536.

Laboratory and clinical studies on cefprozil granules in pediatrics. / Akita, H.; Sato, Y.; Iwata, S.; Sunakawa, K.

In: Japanese Journal of Antibiotics, Vol. 45, No. 11, 1992, p. 1526-1536.

Research output: Contribution to journalArticle

Akita, H, Sato, Y, Iwata, S & Sunakawa, K 1992, 'Laboratory and clinical studies on cefprozil granules in pediatrics', Japanese Journal of Antibiotics, vol. 45, no. 11, pp. 1526-1536.
Akita, H. ; Sato, Y. ; Iwata, S. ; Sunakawa, K. / Laboratory and clinical studies on cefprozil granules in pediatrics. In: Japanese Journal of Antibiotics. 1992 ; Vol. 45, No. 11. pp. 1526-1536.
@article{dbbf6a11193f448c9be1bed7715e7da0,
title = "Laboratory and clinical studies on cefprozil granules in pediatrics",
abstract = "Fundamental and clinical effects of cefprozil (CFPZ, BMY-28 100) granules, a new oral cephalosporin antibiotic, in pediatric field were investigated. The result obtained were summarized as follows. CFPZ (10{\%} granules) was given to 1 child in a single dose of 7.5 mg/kg. The peak serum concentration of CFPZ was 4.51 μg/ml at 2 hours after administration. Half-life and AUC values were 0.98 hour and 20.7 μg · hr/ml. The mean peak urinary concentrations of CFPZ and 6 hours recovery rates were over 200 μg/ml at 2~6 hours and 27.6{\%}, respectively. Clinical efficacy of CFPZ was investigated in a total of 41 children, including 14 with upper respiratory tract infections, 6 with acute bronchitis and pneumonia, 2 with acute otitis media, 3 with skin and soft tissue infections and 16 with urinary tract infections. The clinical efficacy rate was 95.1{\%}. The bacteriological eradication rate was 84.6{\%}. Two patients showed abnormal laboratory test results. One had elevations of both GOT and GPT, and another had eosinophilia which were attributed to this antibiotic as side effects.",
author = "H. Akita and Y. Sato and S. Iwata and K. Sunakawa",
year = "1992",
language = "English",
volume = "45",
pages = "1526--1536",
journal = "The Journal of antibiotics. Ser. B",
issn = "0368-2781",
publisher = "Japan Antibiotics Research Association",
number = "11",

}

TY - JOUR

T1 - Laboratory and clinical studies on cefprozil granules in pediatrics

AU - Akita, H.

AU - Sato, Y.

AU - Iwata, S.

AU - Sunakawa, K.

PY - 1992

Y1 - 1992

N2 - Fundamental and clinical effects of cefprozil (CFPZ, BMY-28 100) granules, a new oral cephalosporin antibiotic, in pediatric field were investigated. The result obtained were summarized as follows. CFPZ (10% granules) was given to 1 child in a single dose of 7.5 mg/kg. The peak serum concentration of CFPZ was 4.51 μg/ml at 2 hours after administration. Half-life and AUC values were 0.98 hour and 20.7 μg · hr/ml. The mean peak urinary concentrations of CFPZ and 6 hours recovery rates were over 200 μg/ml at 2~6 hours and 27.6%, respectively. Clinical efficacy of CFPZ was investigated in a total of 41 children, including 14 with upper respiratory tract infections, 6 with acute bronchitis and pneumonia, 2 with acute otitis media, 3 with skin and soft tissue infections and 16 with urinary tract infections. The clinical efficacy rate was 95.1%. The bacteriological eradication rate was 84.6%. Two patients showed abnormal laboratory test results. One had elevations of both GOT and GPT, and another had eosinophilia which were attributed to this antibiotic as side effects.

AB - Fundamental and clinical effects of cefprozil (CFPZ, BMY-28 100) granules, a new oral cephalosporin antibiotic, in pediatric field were investigated. The result obtained were summarized as follows. CFPZ (10% granules) was given to 1 child in a single dose of 7.5 mg/kg. The peak serum concentration of CFPZ was 4.51 μg/ml at 2 hours after administration. Half-life and AUC values were 0.98 hour and 20.7 μg · hr/ml. The mean peak urinary concentrations of CFPZ and 6 hours recovery rates were over 200 μg/ml at 2~6 hours and 27.6%, respectively. Clinical efficacy of CFPZ was investigated in a total of 41 children, including 14 with upper respiratory tract infections, 6 with acute bronchitis and pneumonia, 2 with acute otitis media, 3 with skin and soft tissue infections and 16 with urinary tract infections. The clinical efficacy rate was 95.1%. The bacteriological eradication rate was 84.6%. Two patients showed abnormal laboratory test results. One had elevations of both GOT and GPT, and another had eosinophilia which were attributed to this antibiotic as side effects.

UR - http://www.scopus.com/inward/record.url?scp=0027080162&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027080162&partnerID=8YFLogxK

M3 - Article

C2 - 1494235

AN - SCOPUS:0027080162

VL - 45

SP - 1526

EP - 1536

JO - The Journal of antibiotics. Ser. B

JF - The Journal of antibiotics. Ser. B

SN - 0368-2781

IS - 11

ER -